Sensitization of Therapeutic-Resistant Pancreatic Cancer by Cancer Cell-Specific Drug Delivery
Abstract
In the first year of this three-year project, we have completed tasks following the timeline of our Statement of Work. We synthesize large amount of HMCD-SIM, enough for the entire project. We determined therapeutic efficacy of the HMCD SIM on pancreatic cancer cell lines; and confirmed the sensitization function of the HMCD-SIM. We have established two new pancreatic cancer cell lines, and tested assay conditions for measuring GASP-1 in clinical serum samples. For mechanistic investigation, we have identified IC50 of the HMCD-SIM in combination with GEM and CDDP in BXPC-3 and MiaPaCa-2 cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2020
- Accession Number
- AD1106348
Entities
People
- James S. Tomlinson
Organizations
- University of California Regents